Academic Journals Database
Disseminating quality controlled scientific knowledge

Long-term efficacy and safety of anastrozole for adjuvant treatment of early breast cancer in postmenopausal women

Author(s): Sharath Gangadhara | Gianfilippo Bertelli

Journal: Therapeutics and Clinical Risk Management
ISSN 1176-6336

Volume: 2009;
Issue: default;
Start page: 291;
Date: 2009;
Original page

Sharath Gangadhara, Gianfilippo BertelliSouth West Wales Cancer Institute, Singleton Hospital, Swansea, UKAbstract: For more than 20 years, tamoxifen has been the gold standard for the adjuvant treatment of postmenopausal women with hormone-responsive early breast cancer. However, recent randomized trials have shown efficacy and tolerability benefits with the third-generation aromatase inhibitor anastrozole, resulting in an increased use of this agent in the adjuvant setting. Data on anastrozole’s long-term efficacy and tolerability are therefore of interest in clinical practice and will be reviewed here, especially in the light of the 100-month analysis of the ATAC (Anastrozole, Tamoxifen Alone or in Combination) trial.Keywords: anastrozole, aromatase inhibitors, breast cancer, adjuvant therapy 

Tango Jona
Tangokurs Rapperswil-Jona

     Save time & money - Smart Internet Solutions